Antineoplastics
1
Reactions 1370 - 24 Sep 2011 Antineoplastics Dysgeusia, leg oedema and numbness: case report A 47-year-old man with metastatic gastric cancer developed dysgeusia and leg oedema while receiving chemotherapy with S-1 and docetaxel; he subsequently developed numbness while receiving paclitaxel and cisplatin [some routes not stated; outcomes not stated]. Following the initial diagnosis, the man underwent a laparotomy. On day 15 after surgery, he commenced S-1 80 mg/m 2 /day, with each course consisting of 2 weeks of dosing and 1 week of rest, as well as IV docetaxel 40 mg/m 2 administered on day 1. On day 24 after surgery, he was discharged. Chemotherapy was continued on an out-patient basis. After 5 months of treatment, he had increased tumour markers; however, disease progression could not be confirmed and chemotherapy was continued. He subsequently developed taste alteration and leg oedema, graded 1–2 according to the Common Terminology Criteria for Adverse Events. He requested changes to the treatment method. Approximately 7 months after surgery, the man’s treatment was switched to paclitaxel 80 mg/m 2 and cisplatin 25 mg/m 2 , with 3 weeks of dosing on days 1, 8 and 15, followed by 1 week of rest. He subsequently reported grade 1 numbness [duration of treatment to reaction onset not stated]. He continued to receive chemotherapy as an out-patient. Yamada K, et al. A case of nonresected gastric cancer with peritoneal dissemination effectively treated by S-1/DOC and PTX/CDDP combination chemotherapy with good QOL. Gan to Kagaku Ryoho 36: 1155-1158, No. 7, Jul 2009 [Japanese; summarised from a translation] - Japan 803060347 1 Reactions 24 Sep 2011 No. 1370 0114-9954/10/1370-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1370 - 24 Sep 2011
Antineoplastics
Dysgeusia, leg oedema and numbness: casereport
A 47-year-old man with metastatic gastric cancerdeveloped dysgeusia and leg oedema while receivingchemotherapy with S-1 and docetaxel; he subsequentlydeveloped numbness while receiving paclitaxel andcisplatin [some routes not stated; outcomes not stated].
Following the initial diagnosis, the man underwent alaparotomy. On day 15 after surgery, he commencedS-1 80 mg/m2/day, with each course consisting of 2 weeksof dosing and 1 week of rest, as well as IV docetaxel40 mg/m2 administered on day 1. On day 24 after surgery,he was discharged. Chemotherapy was continued on anout-patient basis. After 5 months of treatment, he hadincreased tumour markers; however, disease progressioncould not be confirmed and chemotherapy was continued.He subsequently developed taste alteration and legoedema, graded 1–2 according to the CommonTerminology Criteria for Adverse Events. He requestedchanges to the treatment method.
Approximately 7 months after surgery, the man’streatment was switched to paclitaxel 80 mg/m2 andcisplatin 25 mg/m2, with 3 weeks of dosing on days 1, 8 and15, followed by 1 week of rest. He subsequently reportedgrade 1 numbness [duration of treatment to reaction onsetnot stated]. He continued to receive chemotherapy as anout-patient.Yamada K, et al. A case of nonresected gastric cancer with peritonealdissemination effectively treated by S-1/DOC and PTX/CDDP combinationchemotherapy with good QOL. Gan to Kagaku Ryoho 36: 1155-1158, No. 7, Jul2009 [Japanese; summarised from a translation] - Japan 803060347
1
Reactions 24 Sep 2011 No. 13700114-9954/10/1370-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
